Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Atopic dermatitis

This page shows the latest Atopic dermatitis news and features for those working in and with pharma, biotech and healthcare.

Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout

Shionogi makes buyout play for Tetra ahead of Alzheimer’s readout

PDE 4 inhibitors are already used to treat inflammatory diseases in the lungs and skin, such as Amgen’s Otezla (apremilast) for psoriasis and Pfizer’s Eucrisa (crisaborole) for atopic dermatitis.

Latest news

  • Menlo slumps as itching drug fails mid-stage trial Menlo slumps as itching drug fails mid-stage trial

    It’s not the first time that serlopitant has been undermined by a high placebo response rate in trials, however, as the drug previously missed the mark in atopic dermatitis – much

  • Tocagen merges with Forte Biosciences after brain cancer fail Tocagen merges with Forte Biosciences after brain cancer fail

    set to begin in mid-2020 in adults and paediatrics with atopic dermatitis. ... Our team and advisors are committed to providing new treatment options, particularly for paediatrics with atopic dermatitis, for which few treatment options exist, and we look

  • Incyte’s JAK inhibitor cream clears second eczema trial Incyte’s JAK inhibitor cream clears second eczema trial

    Set for regulatory filings later this year. Incyte now has a pair of positive phase 3 trials for its topical formulation of JAK1/2 inhibitor ruxolitinib in atopic dermatitis or eczema, ... The trials recruited patients with mild-to-moderate atopic

  • Vyndaqel a bright spot as Pfizer comes under pressure Vyndaqel a bright spot as Pfizer comes under pressure

    Key candidates coming through late-stage development include JAK1 inhibitor abrocitinib for atopic dermatitis, a vaccine for Clostridium difficile infections, and vaccine against Clostridium difficile and Eli Lilly-partnered tanezumab, which

  • Lilly will aim for one $1bn-$5bn deal per quarter in 2020 Lilly will aim for one $1bn-$5bn deal per quarter in 2020

    The Dermira deal saw Lilly gain both a marketed drug – medicated cloth Qbrexza (glycopyrronium) for uncontrolled excessive underarm sweating – as well as pipeline candidate lebrikizumab for atopic dermatitis, which is currently

More from news
Approximately 10 fully matching, plus 75 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    pneumococcal vaccine due to be filed next year that would extend its $3.4bn Prevnar franchise, a Clostridium difficile vaccine in phase 3 and JAK inhibitors for atopic dermatitis and alopecia.

  • Case study: See Below Case study: See Below

    We needed to pique delegates’ interest and show them a new approach to treating atopic dermatitis. ... But, how? Before diving head-first into the idea, we enlisted the help of key stakeholders within atopic dermatitis.

  • Innovation and digital health comms recognised at Communiqué Awards Innovation and digital health comms recognised at Communiqué Awards

    The video played while the lift whisked its passengers into the congress, creating a six-minute video ‘experience’ which challenged dermatologists to change the way they treated atopic dermatitis. ... In order to target their message, the creative

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... Likewise, upadacitinib will face competition in both RA and atopic dermatitis,

  • Leo has its eyes on the prize Leo has its eyes on the prize

    Innovation investment. Leo has the big beasts of psoriasis and atopic dermatitis firmly in its sights and is forging ahead on the quest to tackle unmet needs in dermatology. ... Bridging the gap. Leo is tracking increases in atopic dermatitis across

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 1 partially matching documents found.

Communiqué Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...

Quick links

Infographics

Multimedia